Ipsen Appoints Mariette Finet to Board of Directors

PARIS, FRANCE, 18 SEPTEMBER 2026 - Ipsen has appointed Mariette Finet to its Board of Directors, effective immediately. Finet, who previously served as a Director, will now co-opt herself into the position, succeeding Michèle Ollier, who resigned on 1 August 2026.

Finet, a Doctor of Medicine and graduate of the University of Nancy, brings over 35 years of experience in the healthcare, pharmaceutical, and life sciences sectors. Her career began in the Medical Department of Laboratoires Beaufour in Paris, where she held roles in pharmaceutical asset analysis and conducted clinical research in various therapeutic areas, particularly focusing on gastroenterology. She later joined Beaufour-Ipsen Pharma and Ipsen, where she held positions in the Marketing Department.

Since 2007, Finet has served in scientific and medical advisory roles at Mayroy and Highrock S.àr.l., providing expertise in investment analysis and portfolio oversight, with a focus on pharmaceutical, MedTech, and life sciences sectors. She also served on the boards of Lightinderm SAS and Kaerus Bioscience Ltd.

In addition to her new role on the Board of Directors, Finet has been appointed to the Board Portfolio Committee, replacing Ollier. Her appointment will be submitted for ratification at the next Annual Shareholders’ Meeting, which is scheduled to convene to approve the financial statements for the year ending 31 December 2026. Subject to ratification, she will serve for the remainder of Ollier’s term.

Following this appointment, Ipsen’s Board of Directors continues to comprise 14 directors, with balanced representation of seven women and seven men, representing 42% of the board, with directors representing employees not taken into account in this calculation, pursuant to article L. 225-18-1 of the French Code of Commerce.

Ipsen, a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas, Oncology, Rare Disease, and Neuroscience, is supported by nearly 100 years of development experience and global hubs in the U.S., France, and the U.K. The company’s teams operate in more than 40 countries, and its partnerships enable it to bring medicines to patients in over 100 countries. For more information, visit Ipsen.